Illumina Stock Rockets 20%+ After Blowout Quarter – What’s Next for ILMN?
Illumina shares surged over 20% to $123.64 by Oct. 31, 2025, after Q3 results beat estimates and guidance was raised. The company completed its Grail divestiture, ending a major EU antitrust case. Former FDA chief Scott Gottlieb became board chair in 2025. Illumina launched a new AI genomics unit and agreed to buy SomaLogic for $350 million.